Fulvestrant in combination with abemaciclib

Phase 3Small molecule

Fulvestrant in combination with abemaciclib is one of 47 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Metastatic Breast CancerRecruiting

Breast CancerPhase 3

Active, not recruiting

Metastatic Breast CancerPhase 3

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adriamycin

GGynecologic Oncology Group

Preclinical

87 2

Fulvestrant in combination with abemaciclib

SSermonix Pharmaceuticals Inc.

Phase 3

1 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 6

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 7

Avastin

Roche

Preclinical

4 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

3 10

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Metastatic Breast Cancer

NCT05696626

Clinical

Trials by Indication[1]

Metastatic Breast Cancer1 trial

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting·SSermonix Pharmaceuticals Inc.·Phase 3·NCT05696626·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fulvestrant in combination with abemaciclib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fulvestrant in combination with abemaciclib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fulvestrant in combination with abemaciclib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sermonix Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSermonix Pharmaceuticals Inc.

Fulvestrant in combination with abemaciclib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Metastatic Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News